Loading
Pharmacology and Obesity Treatment / Obesity and Health Practices · Journal article
Obesity Surgery · August 14, 2026
Encouraging direction, but not yet definitive.
This retrospective cohort study from Portugal reports that metabolic bariatric surgery was associated with reductions in annual medication costs (€56.11 per patient), decreased prevalence of hypertension, type 2 diabetes, dyslipidemia, and asthma, and a 36% reduction in Years Lived with Disability over 3 years. The findings are consistent across multiple outcomes but lack a concurrent control group, so causality cannot be definitively established and secular trends cannot be excluded.
Retrospective cohort study. Portuguese patients with obesity undergoing metabolic bariatric surgery in real-world clinical practice.. Intervention: Metabolic bariatric surgery. Portugal.
Mean annual pharmacotherapy cost decreased by €56.11 per patient 3 years after surgery (p < 0.05) Reductions in medication costs observed for antihypertensive, lipid-lowering, and antidiabetic therapies (all p < 0.05) Prevalence of dyslipidemia, hypertension, type 2 diabetes mellitus and asthma decreased by 32%, 21%, 16% and 5%, respectively, at 3 years
Mean annual pharmacotherapy cost decreased by €56.11 per patient 3 years after surgery (p < 0.05)
Clinicians may use these findings to support counseling on medium-term economic and disease-burden benefits of bariatric surgery in obesity management. However, the lack of a control group limits confidence that improvements are attributable to surgery alone rather than concurrent interventions or secular trends in care.
Real-world retrospective cohort with consistent improvements in medication costs, comorbidity prevalence, and disease burden over 3 years, but lacks control group and randomization, limiting causal inference.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians may use these findings to support counseling on medium-term economic and disease-burden benefits of bariatric surgery in obesity management. However, the lack of a control group limits confidence that improvements are attributable to surgery alone rather than concurrent interventions or secular trends in care.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Obesity is a highly prevalent chronic disease associated with substantial morbidity, multiple comorbidities, and a significant burden on healthcare systems. Metabolic bariatric surgery (MBS) is effective in achieving weight loss and improving obesity-related comorbidities, potentially reducing pharmacotherapy requirements and overall disease burden. Nevertheless, evidence from Portuguese real-world clinical practice remains limited. Therefore, this study aimed to provide the first Portuguese evaluation of the impact of MBS on pharmacotherapy-related healthcare costs and on the prevalence and burden of obesity-associated comorbidities. A retrospective cohort study was conducted. Annual pharmacotherapy costs and changes in the prevalence and burden of obesity-associated comorbidities, measured using Years Lived with Disability (YLD), were compared before and 3 years after surgery. Three years after MBS, the mean annual pharmacotherapy cost per patient decreased by €56.11 (p < 0.05). Reductions in medication costs were observed for antihypertensive, lipid-lowering, and antidiabetic therapies (all p < 0.05). The prevalence of obesity-related comorbidities also decreased, particularly hypertension, type 2 diabetes mellitus, dyslipidemia and asthma (all p < 0.05). Correspondingly, the estimated burden of disease decreased, with mean YLD declining from 0.022 before surgery to 0.014 3 years after surgery (p < 0.05). Over 3 years of follow-up, MBS was associated with reductions in medication costs, the prevalence of obesity-related comorbidities, and overall disease burden. These findings highlight the clinical and economic benefits of MBS in the management of obesity and its associated conditions over the medium term. Metabolic bariatric Surgery reduced mean annual pharmacotherapy costs by €56.11 per patient over a 3-year follow-up. Significant reductions in medication costs were observed for antihypertensive, lipid-lowering, and antidiabetic therapies after metabolic bariatric surgery. The prevalence of dyslipidemia, hypertension, type 2 diabetes mellitus and asthma decreased by 32%, 21%, 16% and 5%, respectively, three years after surgery. Mean Years Lived with Disability (YLD) decreased by 36%, from 0.022 preoperatively to 0.014 at 3 years, indicating a substantial reduction in obesity-related disease burden.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.